PBYI

Puma Biotechnology, Inc.

Sağlık

COMPLIANT — All screening ratios are below the thresholds; the company is compliant with halal investment criteria.

$8.08

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0 / %30

Non-compliant assets / Total market cap %28.1 / %30

Non-compliant revenue / Total income %1.7 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

Website

Analysis (Turkish): PBYI Hissesi Caiz mi, Helal mi? Puma Biotechnology, Inc. Katılım Analizi